Alpha memo: selenium prostate cancer prevention endpoint split

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either reframe the memo around a true shared anchor (e.g., a SELECT secondary analysis that actually splits a selenium effect by population, or contrast the SELECT null against a positive selenium trial) or rename/reclassify as a two-receipt SELECT overview rather than an 'endpoint split.'
2. Provide an actual synthesis paragraph that integrates the two receipts (what each measured, what overlaps, what does not) rather than pasting excerpts into prose.
3. Add an explicit search scope and source inclusion rationale.
4. Name the specific limitation that Receipt 2 measures obesity, not selenium, and therefore cannot adjudicate any selenium endpoint split.

Major issues

• The memo title promises a 'selenium prostate cancer prevention endpoint split' but the two receipts do not form a coherent endpoint-split signal: Receipt 1 is a null trial of selenium/vitamin E for prostate cancer incidence, while Receipt 2 is a secondary SELECT analysis of obesity × race as a risk modifier. The contrast is forced by keyword overlap (both reference SELECT), not by a genuine shared endpoint or intervention comparison.
• The 'bounded population/endpoint split' framing is not actually supported by either receipt. Receipt 1 establishes a null overall result and notes that 'only specific subpopulations may benefit,' but Receipt 2 does not measure selenium; it measures obesity. There is no joint endpoint, no selenium-by-race interaction, and no split of a selenium effect across populations in the cited evidence.
• Receipt content is presented as direct quotes pasted into the one-sentence alpha and 'Why this is surprising' sections without integration or synthesis. The memo reads as copied excerpts stitched together, not as an evidence map.
• No explicit search scope or method is described, and no limits/heterogeneity/mixed findings are acknowledged even though Receipt 1 itself flags formulation, dose, cohort characteristics, and study design as candidate explanations for the null.

Minor issues

• The abstract duplicates the one-sentence alpha verbatim rather than summarizing the bounded signal.
• Caveats are generic (do not generalize, reject on keyword match) and do not name the specific mismatch between selenium null and obesity-race modifier.
• Title/anchor alignment fails: the title says selenium endpoint split, but Receipt 2 carries the entire population-contrast load without a selenium endpoint.

Reviewer note

This submission is structurally broken. The title promises a 'selenium prostate cancer prevention endpoint split,' but the two receipts do not jointly support such a split. Receipt 1 reports the SELECT null result for selenium (and a vitamin E harm signal), explicitly noting that subpopulation effects were not established within the trial. Receipt 2 is a SELECT secondary analysis of obesity × race, with no selenium intervention or endpoint. Stitching them together as a 'population/endpoint split' over 'selenium, prostate, cancer' overclaims beyond what either receipt shows. The prose is largely verbatim excerpts pasted into the abstract and 'Why this is surprising' sections, yielding no synthesis. No search scope is described. The central claim — that there is a bounded population/endpoint split — is not supported by the bundle and cannot be fixed with bounded edits; it requires either a different source pair or a frank reclassification. Reject.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis